SCHEMBL6772415

SCHEMBL6772415

CNC(=NC#N)Nc1cccc(C(=O)OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.59
NPC1 O15118 5/20 0.59
ALDH1A1 P00352 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
TP53 P04637 1/20 0.53
MAPT P10636 5/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HTT P42858 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.47
GPR17 Q13304 1/20 0.47
NPSR1 Q6W5P4 1/20 0.46
ABL1 P00519 1/20 0.46
RIN1 Q13671 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6772413 1.00 RAB9A (0.59) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL6783883 0.86 MEN1 (0.48) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL6783882 0.86 MEN1 (0.48) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL6772591 0.86 RAB9A (0.51) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL6772589 0.86 RAB9A (0.51) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL23455606 0.83 RAB9A (0.65) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL23455604 0.83 RAB9A (0.65) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL6777923 0.83 ALDH1A1 (0.62) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL23455503 0.83 ALDH1A1 (0.62) RAB9ANPC1ALDH1A1SMN1; SMN2TP53
SCHEMBL6777924 0.83 ALDH1A1 (0.62) RAB9ANPC1ALDH1A1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed